William C Daley

US Patent:

20040048905, Mar 11, 2004

Filed:

Jul 31, 2003

Appl. No.:

10/450345

Inventors:

William Daley - Morris Plains NJ, US
Randy Webb - Flemington NJ, US

International Classification:

A61K031/455

US Classification:

514/355000, 514/423000

Abstract:

The present invention especially relates to the use of a combination comprising (1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and (2) amlodipine or pharmaceutically acceptable salt thereof, for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache; wherein (i) the amount of amlodipine or a phamaceutically acceptable salt thereof corresponds to 6 mg to 40 mg of the free base and (ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 mg to 160 mg of benazepril hydrochloride.

US Patent:

20040062787, Apr 1, 2004

Filed:

Aug 11, 2003

Appl. No.:

10/450344

Inventors:

William Daley - Morris Plains NJ, US
Randy Webb - Flemington NJ, US
Ann Comfort - New City NY, US
Santo Fleres - Hillsborough NJ, US
Alan Royce - Saylorsburg PA, US
William Wei - Belle Mead NJ, US

International Classification:

A61F002/00

US Classification:

424/423000

Abstract:

The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a permeable plug.

US Patent:

20080287412, Nov 20, 2008

Filed:

Jul 28, 2008

Appl. No.:

12/180979

Inventors:

Ann R. Comfort - New City NY, US
William L. Daley - Morris Plains NJ, US
Santo J. Fleres - Hillsborough NJ, US
Alan E. Royce - Saylorsburg PA, US
Randy L. Webb - Flemington NJ, US
William S. Wei - Belle Mead NJ, US

International Classification:

A61K 31/55
B05D 3/02
A61P 9/12

US Classification:

51421007, 427 214

Abstract:

The present invention especially relates to the use of a combination comprising(1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and(2) amlodipine or pharmaceutically acceptable salt thereof,for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache;wherein(i) the amount of amlodipine or a pharmaceutically acceptable salt thereof corresponds to 6 about mg to 40 about mg of the free base and(ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 about mg to 160 about mg of benazepril hydrochloride.

US Patent:

20100196467, Aug 5, 2010

Filed:

Apr 16, 2010

Appl. No.:

12/761450

Inventors:

William Lionel Daley - Morris Plains NJ, US
Randy Lee Webb - Flemington NJ, US
Ann Reese Comfort - New City NY, US
Santo Joseph Fleres - Hillsborough NJ, US
Alan Edward Royce - Saylorsburg PA, US
William Shifeng Wei - Belle Mead NJ, US

International Classification:

A61K 31/55
A61K 9/48
A61K 9/66
A61P 9/12
B05D 3/00

US Classification:

424455, 51421207, 424456, 427 214

Abstract:

The present invention especially relates to the use of a combination comprising(1) an ACEI selected from the group consisting of benazepril, benazeprilat, and pharmaceutically acceptable salts thereof, and(2) amlodipine or pharmaceutically acceptable salt thereof, for the manufacture a medicament for the treatment or prevention or delay of progression of a condition selected from the group consisting of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, blood pressure-related cerebrovasular disease, stroke, pulmonary disease or pulmonary hypertension and headache;wherein(i) the amount of amlodipine or a pharmaceutically acceptable salt thereof corresponds to 6 about mg to 40 about mg of the free base and(ii) the amount of the ACE inhibitor or a pharmaceutically thereof corresponds to 20 about mg to 160 about mg of benazepril hydrochloride.

US Patent:

44617550, Jul 24, 1984

Filed:

Jul 14, 1983

Appl. No.:

6/513554

Inventors:

William D. Daley - Morristown NJ
Robert D. Young - Whitehouse Station NJ

Assignee:

Allied Corporation - Morris Township, Morris County NJ

International Classification:

C01B 304
C01B 1704

US Classification:

423573G

Abstract:

A novel process for producing hydrogen and sulfur via the thermal decomposition of hydrogen sulfide is disclosed. The thermal decomposition of hydrogen sulfide is accomplished by passing a hydrogen sulfide containing gas through a reaction chamber containing a refractory material that has been preheated to a temperature between about 982. degree. C. and about 1816. degree. C. so that a gas stream comprising hydrogen, sulfur and hydrogen sulfide is produced. While one reaction chamber is used for decomposition, another is being preheated with hot gases such as a sulfur dioxide-oxygen mixture from a sulfur burner. When the peak temperature in the first reaction chamber declines to a selected value, the functions of the two reaction chambers are reversed.

US Patent:

40396509, Aug 2, 1977

Filed:

May 10, 1976

Appl. No.:

5/684529

Inventors:

William D. Daley - Morristown NJ

Assignee:

Allied Chemical Corporation - Morris Township NJ

International Classification:

C01B 1704

US Classification:

423569

Abstract:

Sulfur dioxide is reduced to sulfur and hydrogen sulfide with a gaseous reducing agent in the presence of a catalyst by a process involving mixing a sulfur dioxide-containing gas stream with a portion of the gaseous reducing agent and passing the resulting mixture through a first reactor to effect reduction of a portion of the sulfur dioxide to hydrogen sulfide and sulfur, mixing the gas stream from the first reactor with the remaining gaseous reducing agent, and splitting the resulting mixture into two gas streams which are in parallel passed through a second and third reactor to effect reduction of sulfur dioxide to form hydrogen sulfide and sulfur. Periodically, the flow in the first and third reactors is reversed to thereby subject these reactors to periodically alternating heat absorbing and desorbing cycles while the flow in the second reactor is always maintained in the same direction. Inlet gas temperatures to the second and third reactors are maintained within desired ranges by by-passing a portion of the sulfur dioxide-containing gas stream and reducing agent around the first reactor.

US Patent:

46438874, Feb 17, 1987

Filed:

Aug 26, 1982

Appl. No.:

6/412051

Inventors:

William D. Daley - Morristown NJ
James Jaffe - Lake Hopatcong NJ

Assignee:

General Chemical Corporation - Morristown NJ

International Classification:

C01B 1774
C01B 1748

US Classification:

423533

Abstract:

A feed gas mixture with SO. sub. 2 partial pressure of at least about 0. 5 atmosphere and an O. sub. 2 :SO. sub. 2 mole ratio of between about 0. 7:1 and about 1:1 is passed in plug flow through a packed bed of conversion catalyst. The catalyst bed is cooled to produce a temperature profile including a first zone of increasing temperature, a second zone of substantially constant temperature and a third zone of declining temperature. The exit temperature is sufficiently low for high equilibrium conversion values. The effluent is cooled to condense liquid sulfur trioxide, while the sulfur trioxide remaining in the gas stream can be absorbed into oleum and/or sulfuric acid. Enriched oleum can be prepared by blending condensed sulfur trioxide into oleum or sulfuric acid.